Nektar Therapeutics (NKTR) said that proof-of-concept data presented by its partner Eli Lilly & Co. showed that, in patients with moderate to severe atopic dermatitis, NKTR-358 (LY3471851) given every two weeks over a 12-week period resulted in a dose-dependent reduction in EASI scores.
At the highest dose tested, the majority of patients maintained the disease reduction for at least 6 months after the last dose of NKTR-358, Nektar said.
The treatment with NKTR-358 at the 24 ug/kg dose resulted in a 70% maximum reduction in EASI scores at week 12.
NKTR-358 is a novel T regulatory (Treg) cell stimulator.
NKTR-358 exhibited a similar tolerability profile in the Phase 1b study in atopic dermatitis as shown in prior studies conducted in patients with mild-to-moderate SLE and healthy volunteers.
Nektar entered into a strategic collaboration with Lilly in 2017 to develop and commercialize NKTR-358.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.